19 June 2013
Keywords: orphan, drug, status, sugen, su101, inc, says
Article | 25 March 1996
Sugen Inc says it has now received an orphan drug designation for its
anticancer compound SU101 in the treatment of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
18 June 2013
© 2013 thepharmaletter.com